RN0051

RN0051 is a preclinical-stage therapeutic candidate being developed by Nanjing Regenecore Biotech (also known as Nanjing Chongyuan Biotechnology) for the treatment of central nervous system (CNS) diseases. The asset is part of the company's pipeline focused on small molecule-induced in situ cellular transdifferentiation, a regenerative medicine approach that aims to convert endogenous non-neuronal cells, such as astrocytes, into functional neurons to repair neural damage. While the specific molecular target of RN0051 has not been publicly disclosed, it is positioned within a platform targeting neurodegenerative and traumatic CNS conditions through chemical reprogramming of resident brain cells.